Replies to post #242337 on Biotech Values

[DewDiligence]

AMRN still has IP protection in Europe, but I’m not sure how long it lasts. Vascepa logged $0.5M (not a typo) of European sales in 1Q22. The PR doesn’t mention this number explicitly, but all you have to do to get it is subtract $93.5M from $94M.